Digestive Diseases and Sciences

, Volume 61, Issue 7, pp 2102–2107 | Cite as

Portal Hypertension Complications Are Frequently the First Presentation of NAFLD in Patients Undergoing Liver Transplantation Evaluation

  • Sajan Jiv Singh Nagpal
  • Mohammad Nasser Kabbany
  • Bashar Mohamad
  • Rocio Lopez
  • Nizar N. Zein
  • Naim Alkhouri
Original Article



Nonalcoholic fatty liver disease (NAFLD) is likely to replace Hepatitis C as the leading cause of cirrhosis resulting in liver transplantation (LT) within a few years. Unfortunately, due to the lack of established guidelines for the screening of NAFLD in high-risk populations, many patients present with portal hypertension complications as their first manifestation of NAFLD require a LT evaluation. We aimed to investigate what proportion of patients who underwent LT for NAFLD-cirrhosis had knowledge of their liver disease prior to presenting with portal hypertension complications and to identify differences in clinical parameters between those with and without knowledge of preexisting NAFLD.


Consecutive patients who underwent LT for NAFLD-cirrhosis at a tertiary referral center were included in the study. Demographic and clinical data at the time of the first LT evaluation visit were collected, and patient knowledge of previous NAFLD was documented. Ascites, variceal bleeding, hepatic encephalopathy, and thrombocytopenia leading to diagnosis of underlying cirrhosis were considered as the presenting symptoms of portal hypertension. A p < 0.05 was considered statistically significant.


A total of 124 subjects who received LT for NAFLD-cirrhosis were included, 58 % (n = 72) were male. At the time of the first LT evaluation visit, 60 % had diabetes, the mean body mass index was 33.2 [28.6, 37.6] kg/m2, and the mean Model for End-Stage Liver Disease (MELD) score was 14.0 [11.0, 19.0]. More importantly, 85/124 patients (68.5 %) had no knowledge of preexisting NAFLD prior to presentation with symptoms of portal hypertension. The presenting symptoms were new-onset ascites in 61 %, hepatic encephalopathy in 25 %, variceal bleeding in 18 %, thrombocytopenia in 9 %, and other in 9 % (non-exclusive). Patients with no prior knowledge of NAFLD were less likely to have a diagnosis of hypercholesterolemia (30 vs. 50 %, p = 0.035) and had a trend toward having higher MELD scores at the time of the first LT evaluation visit (15 vs. 13.5, p = 0.05) and presenting with encephalopathy (25 vs. 10 %, p = 0.06) compared to those with previous knowledge of NAFLD diagnosis.


The majority of patients undergoing liver transplant evaluation for NAFLD-cirrhosis are not aware of underlying NAFLD until they present with features of portal hypertension. New guidelines should consider screening for NAFLD in certain high-risk groups as more effective treatments for NAFLD are emerging.


Nonalcoholic steatohepatitis Cryptogenic cirrhosis Liver transplantation Portal hypertension 



This study was supported by the ACG Junior Faculty Development Award to N.A.

Compliance with ethical standards

Conflict of interest



  1. 1.
    Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2011;9:524.e1–530.e1. (quiz e60).Google Scholar
  2. 2.
    Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatol Baltim Md. 2012;55:2005–2023.CrossRefGoogle Scholar
  3. 3.
    Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148:547–555.CrossRefPubMedGoogle Scholar
  4. 4.
    Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepatic Med Evid Res. 2015;7:51–70.CrossRefGoogle Scholar
  5. 5.
    Ahmed A, Wong RJ, Harrison SA. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015;13:2062–2070.Google Scholar
  6. 6.
    Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 2013;1:38–45.CrossRefGoogle Scholar
  7. 7.
    Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131.CrossRefPubMedGoogle Scholar
  8. 8.
    Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:19–31.CrossRefPubMedGoogle Scholar
  9. 9.
    Gerber LH, Weinstein A, Pawloski L. Role of exercise in optimizing the functional status of patients with nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18:113–127.CrossRefPubMedGoogle Scholar
  10. 10.
    Barrera F, George J. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis. 2014;18:91–112.CrossRefPubMedGoogle Scholar
  11. 11.
    Tham KY, Ong JJ, Tan DK, How KY. How much do diabetic patients know about diabetes mellitus and its complications? Ann Acad Med Singap. 2004;33:503–509.PubMedGoogle Scholar
  12. 12.
    Rhodes KS, Bookstein LC, Aaronson LS, Mercer NM, Orringer CE. Intensive nutrition counseling enhances outcomes of National Cholesterol Education Program dietary therapy. J Am Diet Assoc. 1996;96:1003–1010. (quiz 1011–1012).CrossRefPubMedGoogle Scholar
  13. 13.
    Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann NY Acad Sci. 2013;1281:106–122.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330–344.CrossRefPubMedGoogle Scholar
  15. 15.
    Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004;1:854–858.CrossRefGoogle Scholar
  16. 16.
    Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabetes Med. 2005;1:1141–1145.CrossRefGoogle Scholar
  17. 17.
    Park S-K, Kim NH, Jung YS, et al. Risk of developing advanced colorectal neoplasia after removing high-risk adenoma detected at index colonoscopy in young patients: a KASID Study. J Gastroenterol Hepatol. 2015. doi: 10.1111/jgh.13167.Google Scholar
  18. 18.
    Kwok R, Choi KC, Wong GL-H, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2015. doi: 10.1136/gutjnl-2015-309265.PubMedGoogle Scholar
  19. 19.
    Zoppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E. Mortality from chronic liver diseases in diabetes. Am J Gastroenterol. 2014;109:1020–1025.CrossRefPubMedGoogle Scholar
  20. 20.
    Scaglione S, Kliethermes S, Cao G, et al. The epidemiology of cirrhosis in the united states: a population-based study. J Clin Gastroenterol. 2015;49:690–696.CrossRefPubMedGoogle Scholar
  21. 21.
    Wieland AC, Mettler P, McDermott MT, Crane LA, Cicutto LC, Bambha KM. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk. J Clin Gastroenterol. 2015;49:e6–e10.CrossRefPubMedGoogle Scholar
  22. 22.
    Greene J, Hibbard JH. Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med. 2012;27:520–526.CrossRefPubMedGoogle Scholar
  23. 23.
    Keating SE, Hackett DA, George J, Johnson NA. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57:157–166.CrossRefPubMedGoogle Scholar
  24. 24.
    Huang W-K, Chang JW-C, See L-C, et al. Higher rate of colorectal cancer among patients with pyogenic liver abscess with Klebsiella pneumoniae than those without: an 11-year follow-up study. Colorectal Dis Off J Assoc Coloproctology G B Irel. 2012;14:e794–e801.Google Scholar
  25. 25.
    Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103–107.CrossRefPubMedGoogle Scholar
  26. 26.
    Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet Lond Engl. 2015;14:956–965.CrossRefGoogle Scholar
  27. 27.
    Bergqvist C-J, Skoien R, Horsfall L, Clouston AD, Jonsson JR, Powell EE. Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern Med J. 2013;43:247–253.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Sajan Jiv Singh Nagpal
    • 1
  • Mohammad Nasser Kabbany
    • 2
  • Bashar Mohamad
    • 1
  • Rocio Lopez
    • 3
  • Nizar N. Zein
    • 1
  • Naim Alkhouri
    • 1
    • 2
  1. 1.Department of Gastroenterology and Hepatology and Digestive Disease InstituteCleveland Clinic FoundationClevelandUSA
  2. 2.Department of Pediatric Gastroenterology and HepatologyCleveland ClinicClevelandUSA
  3. 3.Department of Quantitative Health SciencesCleveland ClinicClevelandUSA

Personalised recommendations